6/9/2022 7:23:09 AM
BioCryst Selects Pint Pharma As Commercial Partner For ORLADEYO In Latin America
4/5/2022 7:41:26 AM
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/4/2021 7:29:02 AM
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/20/2021 7:09:03 AM
BioCryst Appoints Amy McKee To Board
6/16/2021 7:08:23 AM
BioCryst Pharma: Israeli Ministry Of Health Accepts Regulatory Submission Of ORLADEYO
6/3/2021 7:13:40 AM
BioCryst Says Oral, Once-daily ORLADEYO Is Now Available For Patients With Prescription In Germany
3/2/2021 7:15:34 AM
BioCryst Submits MAA To UK’s MHRA Seeking Approval Of ORLADEYO To Prevent Attacks In Patients With Hereditary Angioedema
2/3/2021 7:20:34 AM
BioCryst Says FDA Approved Supplemental New Drug Application For RAPIVAB
1/22/2021 7:04:42 AM
BioCryst Secures Approval Of ORLADEYO In Japan
1/6/2016 6:06:29 AM
Jefferies Is Cutting Biocryst Pharmaceuticals Inc (BCRX) 2016 Estimate To -0.54 From -0.41
1/6/2016 6:03:30 AM
Jefferies Ups Biocryst Pharmaceuticals Inc (BCRX) To Buy From Hold With $14 Price Target